DK2269622T3 - Cpg-oligonukleotider anvendt til forøgelse af steroidaktivitet hos en steroidafhængig patient - Google Patents

Cpg-oligonukleotider anvendt til forøgelse af steroidaktivitet hos en steroidafhængig patient Download PDF

Info

Publication number
DK2269622T3
DK2269622T3 DK10162989.7T DK10162989T DK2269622T3 DK 2269622 T3 DK2269622 T3 DK 2269622T3 DK 10162989 T DK10162989 T DK 10162989T DK 2269622 T3 DK2269622 T3 DK 2269622T3
Authority
DK
Denmark
Prior art keywords
oligonucleotide
steroid
use according
patient
administered
Prior art date
Application number
DK10162989.7T
Other languages
English (en)
Inventor
Robert Loefberg
Stein Oliver Von
Arezou Zargari
Original Assignee
Index Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Index Pharmaceuticals Ab filed Critical Index Pharmaceuticals Ab
Application granted granted Critical
Publication of DK2269622T3 publication Critical patent/DK2269622T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Claims (18)

1. Oligonukleotid med sekvensen 5'-Xm-CG-Y n-3' hvor X er A, T, C eller G; Y er A, T, C eller G; m=1 -100, n=1 -100, og hvor mindst ét CG-dinukleotid er umethyleret, til anvendelse ved forbedring af steroidvirkning hos en steroidafhængig patient, der ikke kan vænnes fra systemisk eller topikalt administreret steroidbehandling, og hvor patienten er ramt afen inflammatorisk sygdom.
2. Oligonukleotid til anvendelse ifølge krav 1, hvor den inflammatoriske sygdom er valgt fra gruppen bestående af ulcerativ colitis, Crohns sygdom, reumatoid arthritis, psoriasis, emfysem, astma og kronisk obstruktiv lungesygdom.
3. Oligonukleotid til anvendelse ifølge et hvilket som helst af kravene 1-2, hvor patienten aktuelt er i antiinflammatorisk behandling.
4. Oligonukleotid til anvendelse ifølge et hvilket som helst af de foregående krav, hvor oligonukleotidet omfatter mindst ét nukleotid med en rygradsmodifikation.
5. Oligonukleotid til anvendelse ifølge krav 4, hvor rygradsmodifikationen er en phosphatrygradsmodifikation.
6. Oligonukleotid til anvendelse ifølge krav 5, hvor phosphatrygradsmodifikationen er en phosphorthioat- eller phosphord ith ioatmod if i kation.
7. Oligonukleotid til anvendelse ifølge krav 5, hvor phosphatrygradsmodifikationen indgår i 5'-internukleotidbindingerne eller i 3'-internukleotidbindingerne.
8. Oligonukleotid til anvendelse ifølge et hvilket som helst af de foregående krav, hvor oligonukleotidet er et oligonukleotid sammensat af DNA eller en analog eller et mimetikum af DNA valgt fra gruppen bestående af methylphosphonat, N3'->P5'-phosphoramidat, morpholino, peptidnukleinsyre (PNA), låst nukleinsyre (LNA), arabinosylnukleinsyre (ANA), fluor-arabinosylnukleinsyre (FANA) og methoxy-ethylnukleinsyre (MOE).
9. Oligonukleotid til anvendelse ifølge et hvilket som helst af de foregående krav, hvor oligonukleotidet omfatter mindst én nukleobase med modificeret sukkerdel.
10. Oligonukleotid til anvendelse ifølge krav 9, hvor den modificerede sukkerdel er en 2'-0-methoxyethylsukkerdel.
11. Oligonukleotid til anvendelse ifølge et hvilket som helst af de foregående krav, hvor oligonukleotidet administreres i kombination med steroider.
12. Oligonukleotid til anvendelse ifølge et hvilket som helst af de foregående krav, hvor mængden af oligonukleotid, der administreres til patienten, er ca. 0,01 pg til ca. 100 mg pr. kg legemsvægt.
13. Oligonukleotid til anvendelse ifølge krav 12, hvor mængden af oligonukleotid, der administreres til patienten, er ca. 0,1 pg til ca. 10 mg pr. kg legemsvægt.
14. Oligonukleotid til anvendelse ifølge krav 12, hvor mængden af oligonukleotid, der administreres til patienten, er ca. 1 pg til ca. 5 mg pr. kg legemsvægt.
15. Oligonukleotid til anvendelse ifølge et hvilket som helst af de foregående krav, hvor oligonukleotidet administreres som en enkelt administration.
16. Oligonukleotid til anvendelse ifølge et hvilket som helst af de foregående krav, hvor oligonukleotidet administreres ved mere end en enkelt administration.
17. Anvendelse af et oligonukleotid med sekvensen 5'-Xm-CG-Yn-3' til fremstilling af et lægemiddel til forbedring af steroidvirkning hos en steroidafhængig patient, der ikke kan vænnes fra systemisk eller topikalt administreret steroidbehandling, hvor X er A, T, C eller G; Y er A, T, C eller G; itfI-100, n=1-100, og hvor mindst ét CG-dinukleotid er umethyleret, og hvor patienten er ramt af en inflammatorisk sygdom.
18. Anvendelse ifølge krav 17, hvor den inflammatoriske sygdom er valgt fra gruppen bestående af ulcerativ colitis, Crohns sygdom, reumatoid arthritis, psoriasis, emfysem, astma og kronisk obstruktiv lungesygdom.
DK10162989.7T 2005-07-01 2006-06-29 Cpg-oligonukleotider anvendt til forøgelse af steroidaktivitet hos en steroidafhængig patient DK2269622T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69617305P 2005-07-01 2005-07-01
EP06748068A EP1901759B1 (en) 2005-07-01 2006-06-29 Immunostimulatory method

Publications (1)

Publication Number Publication Date
DK2269622T3 true DK2269622T3 (da) 2014-03-24

Family

ID=37604739

Family Applications (2)

Application Number Title Priority Date Filing Date
DK11166835.6T DK2380584T3 (da) 2005-07-01 2006-06-29 Immunstimulerende fremgangsmåde
DK10162989.7T DK2269622T3 (da) 2005-07-01 2006-06-29 Cpg-oligonukleotider anvendt til forøgelse af steroidaktivitet hos en steroidafhængig patient

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK11166835.6T DK2380584T3 (da) 2005-07-01 2006-06-29 Immunstimulerende fremgangsmåde

Country Status (14)

Country Link
US (2) US8258107B2 (da)
EP (3) EP1901759B1 (da)
JP (3) JP5074392B2 (da)
AT (1) ATE476193T1 (da)
AU (1) AU2006266503B2 (da)
CA (1) CA2612162C (da)
CY (1) CY1114965T1 (da)
DE (1) DE602006015963D1 (da)
DK (2) DK2380584T3 (da)
ES (3) ES2450593T3 (da)
PL (2) PL2380584T3 (da)
PT (1) PT2269622E (da)
SI (2) SI2269622T1 (da)
WO (1) WO2007004977A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2450593T3 (es) * 2005-07-01 2014-03-25 Index Pharmaceuticals Ab Método inmunoestimulante
EP2179737B1 (en) * 2005-07-01 2013-08-14 Index Pharmaceuticals AB Modulating responsiveness to steroids
WO2007050034A1 (en) * 2005-10-28 2007-05-03 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
RU2010112771A (ru) * 2007-10-09 2011-11-20 Коули Фармасьютикал ГмбХ (DE) Иммуностимулирующие аналоги олигонуклеотидов, содержащие модифицированные сахарные группировки
AU2008339090A1 (en) 2007-12-14 2009-06-25 Index Pharmaceuticals Ab Method for predicting the response to a therapy
JP2011524899A (ja) * 2008-06-18 2011-09-08 インデックス・ファーマシューティカルズ・アクチエボラーグ がんの併用療法
US8637479B2 (en) 2008-11-04 2014-01-28 Index Pharmaceuticals Ab Compounds and methods for the treatment of inflammatory diseases of the CNS
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
WO2012065143A1 (en) 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas
EP2596806A1 (en) 2011-11-25 2013-05-29 Index Pharmaceuticals AB Method for prevention of colectomy
EA201492116A1 (ru) 2012-05-16 2015-05-29 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии mecp2
EP3511416A1 (en) 2012-05-16 2019-07-17 Translate Bio MA, Inc. Compositions and methods for modulating gene expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
WO2016070060A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
EP3271460A4 (en) 2015-03-17 2019-03-13 The General Hospital Corporation INTERACTOME RNA OF COMPLEX REPRESSIVE POLYCOMB 1 (PRC1)
JP2019535839A (ja) 2016-11-29 2019-12-12 ピュアテック ヘルス エルエルシー 治療剤の送達のためのエクソソーム
GB201707500D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy
GB201707501D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy 2
GB201707503D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New Therapy 3
GB201807312D0 (en) * 2018-05-03 2018-06-20 Index Pharmaceuticals Ab Formulation

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5652355A (en) * 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
US6346614B1 (en) * 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
TW244371B (da) 1992-07-23 1995-04-01 Tri Clover Inc
CA2105595A1 (en) * 1992-09-23 1994-03-24 Ramaswamy Narayanan Antisense polynucleotides
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6194388B1 (en) 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US20030078223A1 (en) 1996-01-30 2003-04-24 Eyal Raz Compositions and methods for modulating an immune response
DE69739515D1 (de) 1996-01-30 2009-09-10 Univ California Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung.
SE9602300D0 (sv) * 1996-06-11 1996-06-11 Karolinska Innovations Ab New composition and methods
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
JP5087758B2 (ja) 1997-03-10 2012-12-05 オタワ ホスピタル リサーチ インスティチュート アジュバントとして非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
DE69838294T2 (de) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
US6589940B1 (en) * 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
CA2328602A1 (en) 1998-05-06 1999-11-11 University Of Iowa Research Foundation Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
EP1674574A1 (en) * 1998-05-14 2006-06-28 Coley Pharmaceutical GmbH Methods for Regulating Hematopoiesis using CpG-Oligonucleotides
SI1077722T1 (sl) * 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
AU764532B2 (en) 1998-07-27 2003-08-21 University Of Iowa Research Foundation, The Stereoisomers of CpG oligonucleotides and related methods
EE200200158A (et) * 1999-09-25 2003-06-16 University Of Iowa Research Foundation Immunostimulatoorsed nukleiinhapped
EP1688147A1 (en) 1999-09-27 2006-08-09 Coley Pharmaceutical Group, Inc. Methods Related to Immunostimulatory Nucleic Acid-Induced Interferon
MXPA02003059A (es) 1999-09-27 2002-09-30 Univ Iowa Res Found Metodos relacionados con interferon inducido por acido nucleico inmunoestabilizador.
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US7223398B1 (en) * 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20020156033A1 (en) * 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US20020107212A1 (en) 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US6649341B1 (en) * 2000-04-19 2003-11-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Human glucocorticoid receptor 1A promoter and splice variants
EP1296714B1 (en) * 2000-06-22 2009-08-26 University Of Iowa Research Foundation Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
US20020198165A1 (en) * 2000-08-01 2002-12-26 Bratzler Robert L. Nucleic acids for the prevention and treatment of gastric ulcers
ATE510850T1 (de) * 2000-09-15 2011-06-15 Coley Pharm Gmbh Verfahren zum hochdurchsatzscreening von auf cpg basierenden immunagonisten und -antagonisten
US6294382B1 (en) * 2000-11-27 2001-09-25 Isis Pharmaceuticals, Inc. Antisense modulation of SRC-1 expression
WO2002053141A2 (en) 2000-12-14 2002-07-11 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
JP2002257827A (ja) * 2001-03-01 2002-09-11 Jenokkusu Soyaku Kenkyusho:Kk ステロイド応答性の検査方法
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
AU2002256359A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
IL160837A0 (en) * 2001-10-05 2004-08-31 Coley Pharm Gmbh Toll-like receptor 3 signaling agonists and antagonists
JP2005508945A (ja) * 2001-10-06 2005-04-07 メリアル リミテッド Ｃｐｇ配合物及び関連方法
AU2003203079B9 (en) * 2002-02-04 2009-01-15 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
EP1499187B1 (en) * 2002-04-04 2015-06-17 Zoetis Belgium S.A. Immunostimulatory g,u-containing oligoribonucleotides
US20060257851A1 (en) * 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
EP1625140A4 (en) 2002-12-23 2008-06-18 Dynavax Tech Corp BRANCHED IMMUNOMODULAR COMPOUNDS AND METHOD OF USE THEREOF
WO2004058179A2 (en) 2002-12-23 2004-07-15 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
WO2004064782A2 (en) * 2003-01-16 2004-08-05 Hybridon, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
CA2517675A1 (en) * 2003-03-26 2004-10-07 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
WO2004087203A2 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
JP2006528697A (ja) 2003-05-16 2006-12-21 イデラ ファーマシューティカルズ インコーポレイテッド イムノマーを化学療法剤と組み合わせて用いる、癌の相乗的処置
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
US20050158325A1 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Immunomodulatory combinations
CN1918293A (zh) 2004-02-20 2007-02-21 莫洛根股份公司 用于对人及高等动物进行治疗性和预防性免疫刺激的取代的非编码核酸分子
SE0400399D0 (sv) 2004-02-20 2004-02-20 Index Pharmaceuticals Ab Methods and compositions for the treatment or prevention of secondary ischemic injury
JP2007523173A (ja) 2004-02-20 2007-08-16 イデラ ファーマシューティカルズ インコーポレイテッド 修飾免疫調節オリゴヌクレオチドにより誘導された強力な粘膜免疫応答
CA2570786C (en) 2004-06-15 2013-05-28 Idera Pharmaceuticals, Inc. Modified cpg-containing oligonucleotide multimers in immune stimulation
WO2006015560A1 (de) 2004-08-09 2006-02-16 Mologen Ag Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
DK1794174T3 (da) 2004-09-01 2012-07-09 Dynavax Tech Corp Fremgangsmåder og sammensætninger til hæmning af medfødte immunresponser og autoimmunitet
EP1874325A2 (en) * 2005-04-08 2008-01-09 Coley Pharmaceutical Group, Inc. Methods for treating infectious disease exacerbated asthma
EP2179737B1 (en) * 2005-07-01 2013-08-14 Index Pharmaceuticals AB Modulating responsiveness to steroids
ES2450593T3 (es) * 2005-07-01 2014-03-25 Index Pharmaceuticals Ab Método inmunoestimulante

Also Published As

Publication number Publication date
JP2012232988A (ja) 2012-11-29
ATE476193T1 (de) 2010-08-15
US20120277293A1 (en) 2012-11-01
JP2008544983A (ja) 2008-12-11
DK2380584T3 (da) 2014-01-20
ES2450593T3 (es) 2014-03-25
EP1901759B1 (en) 2010-08-04
PL2380584T3 (pl) 2014-03-31
US20100234449A1 (en) 2010-09-16
CY1114965T1 (el) 2016-12-14
EP2269622A1 (en) 2011-01-05
EP2380584B1 (en) 2013-10-16
AU2006266503A1 (en) 2007-01-11
ES2442090T3 (es) 2014-02-10
CA2612162C (en) 2016-05-17
JP2012232989A (ja) 2012-11-29
EP2380584A1 (en) 2011-10-26
SI2269622T1 (sl) 2014-05-30
JP5074392B2 (ja) 2012-11-14
PT2269622E (pt) 2014-03-20
AU2006266503B2 (en) 2011-12-08
CA2612162A1 (en) 2007-01-11
EP1901759A1 (en) 2008-03-26
EP2269622B1 (en) 2013-12-25
WO2007004977A1 (en) 2007-01-11
PL2269622T3 (pl) 2014-05-30
ES2349617T3 (es) 2011-01-07
DE602006015963D1 (de) 2010-09-16
US8592390B2 (en) 2013-11-26
US8258107B2 (en) 2012-09-04
SI2380584T1 (sl) 2014-04-30
JP5945176B2 (ja) 2016-07-05

Similar Documents

Publication Publication Date Title
DK2269622T3 (da) Cpg-oligonukleotider anvendt til forøgelse af steroidaktivitet hos en steroidafhængig patient
EP1904077B1 (en) Modulating responsiveness to steroids
CA2892203C (en) Method for prevention of colectomy
US8895522B2 (en) Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
AU2012200661B2 (en) Immunostimulatory method